PIM1-IN-8 is an inhibitor targeting the PIM1/p65 signaling pathway. It suppresses the expression of α-SMA and type I collagen in activated fibroblasts and inhibits TGF-β-induced migration. In a Bleomycin (BLM)-induced pulmonary fibrosis mouse model, PIM1-IN-8 alleviates lung fibrosis. This compound can be utilized in research on idiopathic pulmonary fibrosis (IPF).

PIM1-IN-8 (Compound B6), when administered at 20-50 μM for 48 hours, exhibits inhibitory activity (IR = 91.2) in TGF-β (10 ng/mL) induced NIH-3T3 cells and maintains high cell viability (VR = 99.7) in GES-1 cells. At concentrations of 3.125-100 μM for 24-48 hours, it inhibits fibroblast activation and proliferation in NIH-3T3 and GES-1 cells when ≥ 50 μM. Furthermore, PIM1-IN-8 at 2.5-10 μM significantly suppresses the expression of α-SMA and type I collagen in NIH-3T3 cells. At 2.5-10 μM for 24 hours, it also blocks TGF-β induced migration in A549 cells.

PIM1-IN-8 (Compound B6), administered at 10-40 mg/kg through intraperitoneal injection for 14 consecutive days, alleviates lung fibrosis in a mouse model induced by Bleomycin (BLM).